Final analysis of KOMET (NCT04924608), a phase 3 study of selumetinib in adults with NF1-PN.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Alice P. Chen, Maria Daniela D'Agostino, Yemima Berman, Angela Swampillai, Renata Colombo Bonadio, Yoshimasa Nobeyama, Jan Styczynski, Maëlla Severino-Freire, Marina Dorofeeva, Silverio Perrotta, Martin Schuhmann, Sergii Derkach, Idoia Herrero, Rosa Lamarca, Randolph de la Rosa, Nereida Llorente, Million Arefayene, Pierre Wolkenstein
Institutions: National Institutes of Health, National Cancer Institute, McGill University Health Centre, McGill University, The University of Sydney, Northern Sydney Local Health District, Guy's and St Thomas' NHS Foundation Trust, D’Or Institute for Research and Education, Jikei University School of Medicine, Antoni Jurasz University Hospital, Collegium Medicum in Bydgoszcz, Centre Hospitalier Universitaire de Toulouse, Pirogov Russian National Research Medical University, University of Campania "Luigi Vanvitelli", University Children's Hospital Tübingen, University of Tübingen, AstraZeneca (Spain), Université Paris-Est Créteil, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Henri-Mondor
Language: English
Subfield: Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162530164
Cites:
Cited by:
Related to: